The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes

Journal of Internal Medicine

Volumn 280, Issue 1, 2016, Pages 24-38

  Rider, L G ^a   Nistala, K ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

chemokine; interferon alpha; juvenile dermatomyositis; juvenile polymyositis; myositis autoantibodies; outcomes

Indexed keywords

AUTOANTIBODY;

CLASSIFICATION; HLA SYSTEM; HUMAN; JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHY; MYOSITIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEROLOGY; SYSTEMATIC REVIEW; UPREGULATION;

EID: 84975142595     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12444     Document Type: Review

References (96)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. Parts 1 and 2. N Engl J Med 1975; 292: 344–7, 3403–407.
2. Tjärnlund A, Bottai M, Rider LG et al. Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2012; 64(Suppl): S323–4.
3. Rider LG, Katz JD, Jones OY. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2013; 39: 877–904.
4. Rider LG, Faiq A, Farhadi PN et al. A58: demographics, clinical features and therapies of patients with juvenile dermatomyositis participating in a national myositis patient registry. Arthritis Rheumatol 2014; 66(Suppl 11): S86–7.
5. Rider LG, Danko K, Miller FW. Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol 2014; 26: 724–41.
6. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011; 305: 183–90.
7. Rider LG, Shah M, Mamyrova G et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92: 223–43.
8. Shah M, Mamyrova G, Targoff IN et al. The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (Baltimore) 2013; 92: 25–41.
9. Pachman LM, Lipton R, Ramsey-Goldman R et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005; 53: 166–72.
10. McCann LJ, Juggins AD, Maillard SM et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)–clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45: 1255–60.
11. Ravelli A, Trail L, Ferrari C et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010; 62: 63–72.
12. Sato JO, Sallum AM, Ferriani VP et al. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 2009; 27: 1031–8.
13. Guseinova D, Consolaro A, Trail L et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 2011; 29: 117–24.
14. Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58: 571–6.
15. Sallum AM, Pivato FC, Doria-Filho U et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 2008; 84: 68–74.
16. Eidelman N, Boyde A, Bushby AJ et al. Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Res Ther 2009; 11: R159.
17. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 2012; 41: 50–8.
18. Sanner H, Gran JT, Sjaastad I, Flato B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009; 48: 1541–7.
19. Wedderburn LR, McHugh NJ, Chinoy H et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007; 46: 1786–91.
20. Aikawa NE, Jesus AA, Liphaus BL et al. Organ-specific autoantibodies and autoimmune diseases in juvenile systemic lupus erythematosus and juvenile dermatomyositis patients. Clin Exp Rheumatol 2012; 30: 126–31.
21. Gheita TA, Fawzy SM, Nour El-Din AM, Gomaa HE. Asymptomatic celiac sprue in juvenile rheumatic diseases children. Int J Rheum Dis 2012; 15: 220–6.
22. Lorenzoni PJ, Scola RH, Kay CS, Prevedello PG, Espindola G, Werneck LC. Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases. Pediatr Neurol 2011; 45: 17–22.
23. Mamyrova G, Katz JD, Jones RV et al. Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. Arthritis Care Res (Hoboken) 2013; 65: 1969–75.
24. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007; 157: 637–44.
25. Mukamel M, Brik R. Amyopathic dermatomyositis in children: a diagnostic and therapeutic dilemma. J Clin Rheumatol 2001; 7: 191–3.
26. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54: 597–613.
27. Plamondon S, Dent PB. Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol 2000; 27: 2031–4.
28. Fujimoto M, Hamaguchi Y, Kaji K et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64: 513–22.
29. Fiorentino DF, Chung LS, Christopher-Stine L et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013; 65: 2954–62.
30. Gunawardena H, Wedderburn LR, North J et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47: 324–8.
31. Bingham A, Mamyrova G, Rother KI et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008; 87: 70–86.
32. Habers GE, Huber AM, Mamyrova G et al. Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis. Arthritis Rheum 2016; 68: 761–768.
33. Shah M, Targoff IN, Rice MM, Miller FW, Rider LG. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum 2013; 65: 1934–41.
34. Tansley SL, Betteridge ZE, Shaddick G et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 2014; 53: 2204–8.
35. Gunawardena H, Wedderburn LR, Chinoy H et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807–14.
36. Kobayashi N, Takezaki S, Kobayashi I et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) 2015; 54: 784–91.
37. Tansley SL, Betteridge ZE, Gunawardena H et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014; 16: R138.
38. Cao H, Pan M, Kang Y et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 2012; 64: 1602–10.
39. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014; 2014: 290797.
40. Hall JC, Casciola-Rosen L, Samedy LA et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65: 1307–15.
41. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65: 25–34.
42. Huber AM, Mamyrova G, Lachenbruch PA et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2014; 66: 732–40.
43. Mammen AL. Necrotizing myopathies: beyond statins. Curr Opin Rheumatol 2014; 26: 679–83.
44. Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008; 35: 927–9.
45. Rider LG, Miller FW, Targoff IN et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37: 1534–8.
46. Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 2013; 48: 477–83.
47. Allenbach Y, Drouot L, Rigolet A et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93: 150–7.
48. Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682–9.
49. Trieu EP, Targoff IN. Immunoprecipitation: Western blot for proteins of low abundance. Methods Mol Biol 2015; 1312: 327–42.
50. Ghirardello A, Rampudda M, Ekholm L et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 2010; 49: 2370–4.
51. Aggarwal R, Oddis CV, Goudeau D et al. Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology (Oxford) 2015; 54: 1194–9.
52. Musset L, Miyara M, Benveniste O et al. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies. J Immunol Res 2014; 2014: 405956.
53. Nakashima R, Imura Y, Hosono Y et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS ONE 2014; 9: e85062.
54. Tansley SL, Betteridge ZE, McHugh NJ. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 2013; 25: 772–7.
55. O'Hanlon TP, Carrick DM, Targoff IN et al. HLA-A, -B, -DRB1 and -DQA1 allelic profiles for the idiopathic inflammatory myopathies: distinct immunogenetic risk and protective factors distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85: 111–27.
56. Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 2015; 52: 189–95.
57. Hashkes PJ, Wright BM, Lauer MS et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010; 62: 599–608.
58. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008; 58: 3585–92.
59. Ponyi A, Constantin T, Balogh Z et al. Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rheumatol 2005; 23: 50–6.
60. Huber AM, Lang BA, LeBlanc CMA et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 541–9.
61. Ladd PE, Emery KH, Salisbury SR, Laor T, Lovell DJ, Bove KE. Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. AJR Am J Roentgenol 2011; 197: W153–8.
62. Miles L, Bove KE, Lovell D et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 2007; 57: 1183–91.
63. Malek A, Raeeskarami SR, Ziaee V, Aghighi Y, Moradinejad MH. Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis. Clin Rheumatol 2014; 33: 1113–8.
64. Hoeltzel MF, Becker ML, Robinson AB, Feldman BM, Huber A, Reed AM. Race is a risk factor for calcinosis in patients with JDM - early results from the CARRAnet registry study. Pediatr Rheumatol Online J 2012; 10(Suppl 1): A65.
65. Mamyrova G, O'Hanlon TP, Sillers L et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008; 58: 3941–50.
66. Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 2009; 23: 665–78.
67. Rayavarapu S, Coley W, Kinder TB, Nagaraju K. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle 2013; 3: 13.
68. Miller FW, Cooper RG, Vencovsky J et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 2013; 65: 3239–47.
69. Liu Y, Ramot Y, Torrelo A et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012; 64: 895–907.
70. Lee PY, Li Y, Richards HB et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3759–69.
71. Lopez de Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009; 60: 1160–72.
72. Bilgic H, Ytterberg SR, Amin S et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436–46.
73. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865–74.
74. Balboni I, Niewold TB, Morgan G et al. Interferon-alpha induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum 2013; 65: 2424–9.
75. Higgs BW, Zhu W, Morehouse C et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014; 73: 256–62.
76. Sanner H, Sjaastad I, Flato B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 2014; 53: 1578–85.
77. Schwartz T, Sjaastad I, Flato B, Vistnes M, Christensen G, Sanner H. In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction. Rheumatology (Oxford) 2014; 53: 2214–22.
78. Enders FB, Delemarre EM, Kuemmerle-Deschner J et al. Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity. Ann Rheum Dis 2015; 74: 315–7.
79. Bellutti EF, Van Wijk F, Scholman R et al. Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis. Arthritis Rheumatol 2014; 66: 2281–9.
80. Wedderburn LR, Varsani H, Li CK et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007; 57: 1192–201.
81. Varsani H, Charman SC, Li CK et al. Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Ann Rheum Dis 2015; 74: 204–10.
82. Nagaraju K, Raben N, Loeffler L et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000; 97: 9209–14.
83. Nagaraju K, Casciola-Rosen L, Lundberg I et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 1824–35.
84. Li CK, Knopp P, Moncrieffe H et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 2009; 175: 1030–40.
85. Burzyn D, Kuswanto W, Kolodin D et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013; 155: 1282–95.
86. Villalta SA, Rosenthal W, Martinez L et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med 2014; 6: 258ra142.
87. Vercoulen Y, Bellutti EF, Meerding J et al. Increased presence of FOXP3 + regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood. PLoS ONE 2014; 9: e105353.
88. Hinds DA, McMahon G, Kiefer AK et al. A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci. Nat Genet 2013; 45: 907–11.
89. Wu YY, Georg I, Diaz-Barreiro A et al. Concordance of Increased B1 Cell Subset and Lupus Phenotypes in Mice and Humans Is Dependent on BLK Expression Levels. J Immunol 2015; 194: 5692–702.
90. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010; 207: 2053–63.
91. Sanner H, Schwartz T, Flato B, Vistnes M, Christensen G, Sjaastad I. Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage. PLoS ONE 2014; 9: e92171.
92. Nistala K, Varsani H, Wittkowski H et al. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Res Ther 2013; 15: R131.
93. Liprandi A, Bartoli C, Figarella-Branger D, Pellissier JF, Lepidi H. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol 1999; 97: 642–8.
94. Seeliger S, Vogl T, Engels IH et al. Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. Am J Pathol 2003; 163: 947–56.
95. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845–9.
96. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323–9.